Bayer Company Profile

What is the competitive landscape for BAYER

BAYER has one hundred and twenty-six approved drugs.

There are sixty-two US patents protecting BAYER drugs. There is one tentative approval on BAYER drugs.

There are one thousand two hundred and eighty-six patent family members on BAYER drugs in sixty-one countries and two hundred and six supplementary protection certificates in twenty-one countries.

Summary for Bayer

International Patents:	1286
US Patents:	62
Tradenames:	111
Ingredients:	75
NDAs:	126
Patent Litigation for Bayer:	See patent lawsuits for Bayer

Drugs and US Patents for Bayer

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	PRECOSE	acarbose	TABLET;ORAL	020482-001	Sep 6, 1995		DISCN	Yes	No
Bayer Hlthcare	VITRAKVI	larotrectinib sulfate	CAPSULE;ORAL	210861-002	Nov 26, 2018		RX	Yes	Yes	9,127,013		Y	Y
Bayer Hlthcare	CLIMARA	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	020375-005	May 27, 2003	AB2	RX	Yes	No
Bayer Pharms	MEZLIN	mezlocillin sodium monohydrate	INJECTABLE;INJECTION	062333-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Bayer Hlthcare	STIVARGA	regorafenib	TABLET;ORAL	203085-001	Sep 27, 2012		RX	Yes	Yes	9,458,107		Y
Bayer Hlthcare	QUINACT	quinidine gluconate	TABLET;ORAL	086099-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for Bayer

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	BEYAZ	drospirenone; ethinyl estradiol; levomefolate calcium	TABLET;ORAL	022532-001	Sep 24, 2010	RE37564
Bayer Hlthcare	SAFYRAL	drospirenone; ethinyl estradiol; levomefolate calcium	TABLET;ORAL	022574-001	Dec 16, 2010	6,441,168
Bayer Hlthcare	LEVITRA	vardenafil hydrochloride	TABLET;ORAL	021400-001	Aug 19, 2003	8,841,446
Bayer Hlthcare	CIPRO	ciprofloxacin	FOR SUSPENSION;ORAL	020780-001	Sep 26, 1997	6,136,347*PED
Bayer Hlthcare	CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER	ciprofloxacin	INJECTABLE;INJECTION	019857-001	Dec 26, 1990	4,705,789*PED
Bayer Hlthcare	LEVITRA	vardenafil hydrochloride	TABLET;ORAL	021400-002	Aug 19, 2003	7,696,206

Paragraph IV (Patent) Challenges for BAYER drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	3 mg/0.02 mg		2006-09-29
	Injection	1.6 mg/mL		2014-02-07
	Tablets	0.5 mg, 1 mg,1.5 mg, 2 mg and2.5 mg		2017-10-10
	Tablets	0.25 mg/0.5 mg		2015-01-08
	Tablets	3 mg/0.02 mg/0.451 mg and 0.451 mg		2012-11-13
	Tablets	5 mg ad 10 mg		2009-07-10
	Tablets	3 mg; 2 mg/2 mg; 2 mg/3 mg; 1 mg		2010-10-22
	Tablets	25 mg, 50 mg and 100 mg		2005-03-22
	Tablets	40 mg		2016-09-27
	Oral Suspension	250 mg/5 mL and 500 mg/ 5 mL		2009-10-16
	Tablets	3 mg/0.03 mg		2005-01-07
	Orally Disintegrating Tablets	10 mg		2011-12-22
	Tablets	0.5 mg/1 mg		2007-12-26
	Tablets	3 mg/0.02 mg/0.451 mg and 0.451 mg		2011-11-21
	Tablets	20 mg		2009-03-05
	Tablets	2.5 mg		2009-09-04
	Tablets	200 mg		2014-02-28
	Tablets	3 mg/0.03 mg/0.451 mg and 0.451 mg		2012-09-28
	Transdermal System	0.05 mg/day and 0.1 mg/day		2005-09-12

International Patents for Bayer Drugs

Country	Patent Number	Estimated Expiration
Mexico	2019013714
Poland	2486942
Ecuador	SP077356
San Marino	T201400138
Australia	2022204806
Slovenia	3372605

Supplementary Protection Certificates for Bayer Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1411900	18/2011	Austria		PRODUCT NAME: NAPROXEN UND ESOMEPRAZOL SOWIE DEREN PHARMAZEUTISCH ANNEHMBARE SALZE; NAT. REGISTRATION NO/DATE: 1-29937 20110105; FIRST REGISTRATION: GB PL 17901/0263-0001 20101105
1663978	C 2014 007	Romania		PRODUCT NAME: REGORAFENIB SI SARURILE SALE4-[4-({[4-CLORO-3-(TRIFLUOROMETIL)-FENIL]CARBAMOIL}AMINO)-TIONAL AUTHORISATION: 20130826; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/858; DATE OF FIRST AUTHORISATION IN EEA: 20130826 3-FLUOROFENOXI]-N-METILPIRIDIN-2-CARBOXAMIDA; NATIONAL AUTHORISATION NUMBER: EU/1/13/858; DATE OF NA
1429780	122012000070	Germany		PRODUCT NAME: KOMBINATION AUS CIPROFLOXACIN UND DEXAMETHASON, INSBESONDERE CIPROFLOXACINHYDROCHLORID UND DEXAMETHASON; NAT. REGISTRATION NO/DATE: 85150.00. 00 20120830; FIRST REGISTRATION: DAENEMARK 48976 20120808
0771217	07C0001	France		PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
3106463	2020C/507	Belgium		PRODUCT NAME: VITRAKVI - LAROTRECTINIB ET/OU SES SELS ACCEPTABLES EN PHARMACIE, EN PARTICULIER L'HYDROGENO SULFATE DE LAROTRECTINIB; AUTHORISATION NUMBER AND DATE: EU/1/19/1385 20190923
1140840	PA2006008,C1140840	Lithuania		PRODUCT NAME: SORAFENIBAS IR FARMACINIU POZIURIU PRIIMTINOS JO DRUSKOS; REGISTRATION NO/DATE: EU/1/06/342/001 20060719

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Bayer
• Bayer Healthcare
• Bayer Healthcare Llc
• Bayer Hlthcare
• Bayer Pharms

Bayer: Market Position, Strengths, and Strategic Insights

Last updated: March 14, 2026

Summary: Bayer maintains a leading position in global pharmaceuticals, focusing on innovative therapies and diversified portfolio management. It invests heavily in R&D, with strategic acquisitions expanding its pipeline. Bayer faces competitive pressure from companies like Pfizer, Novartis, and Roche, especially in oncology and cardiology segments. Its emphasis on digital health and sustainability initiatives supports long-term growth.

What Is Bayer's Market Position in the Pharmaceutical Industry?

Bayer ranks among the top 20 pharmaceutical companies globally by revenue. It generated approximately €19 billion in 2022, with roughly 60% from pharmaceuticals, 20% from consumer health, and 20% from crop sciences, though the latter is outside the core pharma focus. It holds significant market share in specific segments:

• Oncology: One of the top players with blockbuster drugs like Nexavar (sorafenib) and Xarelto (rivaroxaban).
• Hemophilia: Influential via therapies like Kogenate.
• Cardiovascular diseases: Dominant with anticoagulants like Xarelto.

Market Share Comparison (2022):

Company	Estimated Revenue (€B)	Key Focus Areas	Market Share in Oncology(%)
Bayer	19	Oncology, Hematology, CV	8.5
Pfizer	81	Oncology, Vaccines	20
Novartis	51	Oncology, Ophthalmology	9
Roche	62	Oncology, Diagnostics	15

Bayer's focused approach on targeted therapies and digital health enhances its competitive stance.

What Are Bayer's Core Strengths?

Innovative R&D Capability

Bayer allocates approximately 15% of sales to R&D annually. Its core R&D strengths include:

• Strategic collaborations with biotech firms (e.g., Aura Biosciences).
• Focus on precision medicine, notably in oncology.
• Proven track record of drug approvals, with 15 New Molecular Entities (NMEs) between 2018-2022.

Diversified Portfolio

The company's dual focus on pharmaceuticals and consumer health stabilizes revenue streams:

• Pharmaceuticals: Oncology, cardiology, neurology.
• Consumer Health: Aspirin, dietary supplements, dermatology products.

Global Presence

Bayer sells in over 100 countries; its pipeline benefits from access to emerging markets, especially in Asia and Latin America, where healthcare expenditure grows rapidly.

Digital and Sustainability Initiatives

• Deployment of AI for drug discovery.
• Investment in environmental sustainability: aim for climate neutrality by 2030.
• Digital health ventures like Gateway Health and partnerships with telehealth companies.

What Strategic Moves Does Bayer Make to Sustain Growth?

Acquisition Strategy

Bayer invests in acquiring innovative companies to increase pipeline strength:

• Acquisition of AskBio in 2021 for gene therapy expansion.
• Partnership with Maser Diagnostics to advance personalized medicine.

Portfolio Optimization

In 2022, Bayer divested units outside core pharma focus, including plant biotech assets, reallocating capital to high-growth sectors.

Digital Transformation

• Implemented cloud-based data analysis.
• Launched digital platforms for clinical trial management.
• Collaborates with tech firms like Google for healthcare data analytics.

Market Expansion Efforts

• Focus on emerging markets where regulatory environments are favorable.
• Tailored pricing strategies for low-income countries to increase access.

What Are the Main Challenges Facing Bayer?

Patent Expirations

Loss of exclusivity on key drugs like Xarelto (2024) and other patents pressures revenue.

Pricing Pressures

Governments and payers push for reduced drug prices globally, especially in Europe and the US.

Intense Competition

Pfizer, Novartis, Roche, and newer biotech firms challenge Bayer’s market share with innovative therapies and biologics.

Regulatory and Patent Risks

Stringent approval processes, especially for gene therapies and digital health solutions, increase development timelines and costs.

What Are the Growth Opportunities?

• Expansion of oncology portfolio through in-house R&D and acquisitions.
• Growth in digital health investments, including remote monitoring and AI-enabled diagnostics.
• Further penetration into emerging markets with unmet medical needs.
• Development of biosimilar pipeline to capitalize on patent cliffs.

What Are the Key Takeaways?

• Bayer holds a robust global pharmaceutical portfolio with a focus on oncology, hematology, and cardiology.
• The company’s strengths include significant R&D investment, diversified operations, and digital initiatives.
• Strategic acquisitions and portfolio optimization underpin its growth strategy.
• Competition remains fierce, with patent expirations and pricing pressures acting as primary risks.
• Opportunities exist in digital health, emerging markets, and biosimilars to sustain long-term growth.

FAQs

1. How does Bayer's R&D investment compare to competitors?
Bayer spends approximately 15% of sales on R&D annually, above industry averages (~12-14%), emphasizing innovation. This compares favorably to Novartis (~15%), Pfizer (~12%), and Roche (~14%).

2. What are Bayer’s key drugs expected to lose patent protection soon?
Xarelto's patent is set to expire in 2024. Other drugs under patent include Adempas (riociguat) and Alpharadin (radium-223). Loss of exclusivity impacts revenue, prompting pipeline expansion.

3. How does Bayer leverage digital health?
It deploys AI in drug discovery, digital platforms in clinical trials, and collaborates with tech firms for telehealth solutions, aiming to reduce costs and accelerate development timelines.

4. What is Bayer’s strategy for emerging markets?
Bayer tailors pricing, partners with local governments, and invests in manufacturing capacity to capture growth in Asia, Latin America, and Africa.

5. How focused is Bayer on sustainability?
Bayer aims for climate neutrality by 2030, reducing greenhouse gas emissions and increasing eco-friendly manufacturing. It also invests in sustainable agriculture through its crop science division.

---

References

1. Bayer. (2022). Annual Report 2022. Retrieved from https://www.bayer.com
2. IQVIA. (2022). The Global Use of Medicines in 2022. IQVIA Institute.
3. Statista. (2022). 2022 Global Pharmaceutical Market Revenue.
4. Reuters. (2022). Bayer’s strategic review and market analysis.
5. Harvard Business Review. (2021). Digital Transformation in Pharma.